

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 April 2022 (21.04.2022)



(10) International Publication Number
WO 2022/077115 A1

(51) International Patent Classification:

C12N 5/10 (2006.01) *C07K 14/515* (2006.01)
A61K 35/28 (2015.01) *C07K 14/705* (2006.01)
A61P 31/12 (2006.01) *C12N 15/12* (2006.01)
A61P 31/14 (2006.01) *C12N 15/85* (2006.01)
A61P 31/16 (2006.01) *C12N 5/0775* (2010.01)

(72) Inventors: **MEI, Shirley H.J.**; 1885 Dauphin Road, Ottawa, Ontario K1G 2L4 (CA). **DE SOUZA MOREIRA, Luciana**; 233 Stroget Private, Ottawa, Ontario K2E 0A9 (CA). **TAN, Yuan**; 262 Freedom Private, Ottawa, Ontario K1G 6W2 (CA). **WANG, Yanc**; 1825 Russel Road, Unit 409, Ottawa, Ontario K1G 3T4 (CA).

(21) International Application Number:

PCT/CA2021/051448

(74) Agent: **LAVERY, DE BILLY, LLP**; 1, Place Ville Marie, Bureau 4000, Montréal, Québec H3B 4M4 (CA).

(22) International Filing Date:

15 October 2021 (15.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/092,572 16 October 2020 (16.10.2020) US

(71) Applicant: **OTTAWA HOSPITAL RESEARCH INSTITUTE** [CA/CA]; 501 Smyth Road, Ottawa, Ontario K1H 8L6 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: CELL-BASED THERAPY FOR VIRAL DISEASES




FIG. 5A

(57) Abstract: The present application relates to the prevention or treatment of symptoms and diseases caused by viral infections, such as acute respiratory distress syndrome (ARDS), sepsis or septic shock associated with SARS-CoV-2 and influenza virus infections. The treatment is based on the use of mesenchymal stem cells (MSCs) genetically engineered to overexpress suitable polypeptides such as angiopoietin-1 (ANGPT1) and IFN-induced transmembrane (IFITM). The MSC-based therapy may be administered to the lung of the patient by injection into the blood system.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*